The New England journal of medicine, 2018-02, Vol.378 (8), p.699-707
- Anderson, David R
- Dunbar, Michael
- Murnaghan, John
- Kahn, Susan R
- Gross, Peter
- Forsythe, Michael
- Pelet, Stephane
- Fisher, William
- Belzile, Etienne
- Dolan, Sean
- Crowther, Mark
- Bohm, Eric
- MacDonald, Steven J
- Gofton, Wade
- Kim, Paul
- Zukor, David
- Pleasance, Susan
- Andreou, Pantelis
- Doucette, Steve
- Theriault, Chris
- Abianui, Abongnwen
- Carrier, Marc
- Kovacs, Michael J
- Rodger, Marc A
- Coyle, Doug
- Wells, Philip S
- Vendittoli, Pascal-Andre
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Anderson, David R
- Dunbar, Michael
- Murnaghan, John
- Kahn, Susan R
- Gross, Peter
- Forsythe, Michael
- Pelet, Stephane
- Fisher, William
- Belzile, Etienne
- Dolan, Sean
- Crowther, Mark
- Bohm, Eric
- MacDonald, Steven J
- Gofton, Wade
- Kim, Paul
- Zukor, David
- Pleasance, Susan
- Andreou, Pantelis
- Doucette, Steve
- Theriault, Chris
- Abianui, Abongnwen
- Carrier, Marc
- Kovacs, Michael J
- Rodger, Marc A
- Coyle, Doug
- Wells, Philip S
- Vendittoli, Pascal-Andre
- Titel
- Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
- Ist Teil von
- The New England journal of medicine, 2018-02, Vol.378 (8), p.699-707
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a large, randomized trial involving patients undergoing knee or hip arthroplasty, aspirin was found to be noninferior to rivaroxaban in clot prevention and had a similar risk of serious bleeding.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1712746Titel-ID: cdi_proquest_miscellaneous_2007425799
- Format
- –
- Schlagworte
- Aged, Anticoagulants, Arthroplasty (knee), Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Aspirin, Aspirin - adverse effects, Aspirin - therapeutic use, Bleeding, Clinical trials, Double-Blind Method, Embolism, Factor Xa Inhibitors - adverse effects, Factor Xa Inhibitors - therapeutic use, Health risk assessment, Hemorrhage - chemically induced, Hip, Hip joint, Humans, Joint surgery, Knee, Male, Middle Aged, Platelet Aggregation Inhibitors - adverse effects, Platelet Aggregation Inhibitors - therapeutic use, Postoperative Complications - prevention & control, Prophylaxis, Risk Factors, Rivaroxaban - adverse effects, Rivaroxaban - therapeutic use, Thromboembolism, Thrombosis, Total hip arthroplasty, Veins & arteries, Venous Thromboembolism - prevention & control